01 — At a Glance
When A Hospital Network Plays Venture Capitalist
- 52-Week High / Low₹2,372 / 1,380
- Q3 Revenue₹2,151 Cr
- Q3 PAT₹127 Cr
- Q3 EPS₹6.20
- Full-Year EPS (FY25)₹38.66
- Book Value₹199
- Price to Book8.82x
- Dividend Yield0.26%
- Debt / Equity0.58x
- EV / EBITDA24.2x
The Setup: Narayana Hrudayalaya is India’s fourth-largest hospital chain by market cap (₹35,947 Cr). Q3 revenue hit ₹2,151 Cr (+61% YoY, but that includes the UK acquisition impact). Consolidated net profit was ₹127 Cr, down 12.8% YoY due to exceptional charges (labour code adjustments, integration costs). The firm now operates 42 healthcare facilities across India and Cayman Islands with 5,554 beds. But here’s the spice: they just dropped ₹2,200 crore on acquiring UK Practice Plus Group hospitals in November 2025. Stock trades at a chunky 43.6x P/E. Everyone’s asking: growth machine or debt ticking time bomb?
02 — Introduction
The Hospital Chain That Went Global (Overnight)
Let me paint you a picture. It’s 2025. India’s healthcare sector is on a growth binge. Private hospital chains are expanding. Occupancy is humming. Margins are healthy. Everything is going according to plan.
Then Dr. Devi Prasad Shetty and team decide: “You know what? Let’s also buy a hospital chain in the UK. For ₹2,200 crore. Because why not?” And just like that, Narayana Hrudayalaya shifted from being a focused Indian healthcare play to becoming an international multi-geography operator. The audacity is either genius or terrifying. Sometimes both.
Founded in 1990, Narayana Health has been India’s poster child for “affordable premium healthcare” — the sweet spot where you get world-class cardiac surgery at a fraction of Apollo or Max Healthcare prices. Promoter Devi Prasad Shetty is a legend (Padma Bhushan awardee). The brand is strong. The execution has been solid. But Q3 FY26 results revealed something new: aggressive expansion mode. Not just in India. Globally. With debt. Lots of debt.
Let’s dissect what Narayana Hrudayalaya actually is, why they bought UK hospitals, whether that makes financial sense, and if the stock at ₹1,759 is priced for perfection or priced for pain.
Concall Highlight (Feb 2026): Management said they are moving away from reporting occupancy: “We are not in the hotel business and occupancy matters less to us.” Translation: focus on patient volumes, not bed utilization metrics. Fair. But when you’re carrying ₹2,428 crore in debt post-UK acquisition, every bed better be printing money.
03 — Business Model: Healthcare, But Make It Fancy
Who Needs Just India When You Can Have India + Cayman + UK?
Narayana Health operates multi-specialty hospitals focused on cardiac sciences, oncology, renal sciences, and neurosurgery. The classic model: build a hospital, hire world-class doctors, invest in robotic surgery tech, set prices 30–50% lower than Apollo/Max, and let the volume math work out. ARPOB (Average Revenue Per Operating Bed) is now ₹1.49 lakhs per patient in domestic ops. That’s the metric that matters in hospital franchises — not occupancy.
Revenue mix is split across three geographies: India domestic (~80%), Cayman Islands (~10%), and now post-November 2025, UK Practice Plus operations (~5–10% forward). The payor mix domestically is 47% walk-ins, 31% insured patients, 18% government schemes. It’s diversified, which is good. But government reimbursement caps are real headwinds.
Specialty-wise, cardiac accounts for 33% of revenue (their moat), oncology jumped to 15% (rapidly becoming the #2 revenue driver), and the rest is spread across medicines, renal sciences, neuro, and orthopedics. The management’s stated intent is to build an “integrated stack” — hospitals + clinics + insurance + wellness services — so they capture the entire year-round health spend, not just acute tertiary care episodes.
Cardiac Revenue33%Flagship Specialty
Oncology15%Fastest Growing
Operating Beds5,554Total Capacity
Hospitals20India + Cayman
The Risky Bit: Bangalore alone contributed 36% of revenue. Kolkata another 26%. High concentration on two cities. If there’s competition (and there is — more hospitals are coming to both clusters), margins compress. Management is aware and is building hospitals in tier-2 cities (Raipur, Jaipur, Ahmedabad). But that takes time. And capex. Lots of it.
04 — Financials Overview: Q3 FY26
The Numbers (With Some Asterisks)
Result type: Quarterly Results | Q3 FY26 EPS: ₹6.20 | Annualised EPS (Q3×4): ₹24.80 | Full-year FY25 EPS: ₹38.66
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 2,151 | 1,335 | 1,644 | +61.2% | +30.8% |
| Operating Profit | 365 | 307 | 401 | +19.0% | -8.9% |
| OPM % | 17% | 23% | 24% | -600 bps | -700 bps |
| PAT | 127 | 193 | 258 | -34.2% | -50.8% |
| EPS (₹) | 6.20 | 9.44 | 12.64 | -34.3% | -50.9% |
The Catch: Revenue growth is bonkers at 61.2% YoY, but that’s because Q3 FY26 includes the UK Practice Plus acquisition (effective Nov 6, 2025). Strip that out and domestic growth is closer to 15–20%, which is healthy but not revolutionary. More importantly, OPM crashed 600 bps YoY to 17% because of: (a) labour code charge of ₹509 crore (one-time), (b) integration costs from the UK deal, and (c) dilution from Cayman Island operations (still scaling). PAT fell 34% YoY. That’s painful on the eye. But once you factor out exceptional items, the underlying business is growing decently.
05 — Valuation: Fair Value Range
Is ₹1,759 Expensive? Spoiler: Yes. Depending On What You Believe.
Join 10,000+ investors who read this every week.
